Registry of Lobbyists
| Subject matters | Details | Categories |
|---|---|---|
|
Health, Industry, Research and Development, Science and Technology
|
Canada’s Drug Agency policy frameworks and processes related to reimbursement recommendations, including decision‑making approaches and timelines.
|
Policies or Program, Regulation
|
|
Budget, Health, Industry
|
Engagement on federal budget priorities and updates affecting the biopharmaceutical sector, including implications for patient access to innovative medicines, vaccines, and therapies.
|
Policies or Program
|
|
Federal-Provincial Relations, Health, Industry
|
Engagement on federal policies and frameworks that support improved coordination across jurisdictions to facilitate timely patient access following Health Canada approval.
|
Regulation, Policies or Program
|
|
Health
|
Engagement on federal policies and programmes related to the availability, appropriate use, and continuity of supply of plasma‑derived therapies, including immunoglobulins, for patients with immune‑mediated and rare conditions.
|
Policies or Program
|
|
Health, Internal Trade
|
Engagement on international trade discussions and policies that may impact access to medicines and the security of drug supply in Canada.
|
Policies or Program
|
|
Government Procurement, Health
|
Federally funded public drug plans, including programmes for Indigenous Peoples, veterans, and federal plan beneficiaries, with respect to reimbursement of therapeutic products.
|
Policies or Program
|
|
Health
|
Health Canada policies and guidance related to the prevention, monitoring, and management of drug shortages.
|
Policies or Program, Regulation
|
|
Health, Industry, Research and Development
|
Health Canada regulatory modernisation initiatives, including regulatory innovation, flexibility, predictability, and alignment with international approaches.
|
Policies or Program
|
|
Industry, Research and Development
|
Innovation, Science and Economic Development Canada initiatives and programmes supporting life sciences research, development, and advanced therapies conducted in Canada.
|
Policies or Program
|
|
Federal-Provincial Relations, Health
|
Monitoring and engagement on federal roles in health system planning and preparedness as they relate to blood‑related products and plasma‑derived medicines used in federally funded programmes and public health responses.
|
Policies or Program
|
|
Health
|
Monitoring and engagement on legislation, regulations, and policies related to national pharmacare, including implementation of relevant federal Acts.
|
Regulation, Policies or Program, Legislative Proposal, Bill or Resolution
|
|
Health
|
Monitoring and engagement on the Government of Canada’s National Strategy for Rare Diseases, including related policy frameworks and implementation considerations.
|
Policies or Program
|
|
Health, Industry, Intellectual Property
|
Pharmaceutical pricing policy considerations within the mandate of the Patented Medicine Prices Review Board (PMPRB), including regulatory amendments and associated guidance.
|
Policies or Program, Regulation
|
|
Health, Industry, Research and Development
|
Policies and programmes related to Canada’s Biomanufacturing and Life Sciences Strategy, including support for research, innovation, and manufacturing capability in Canada.
|
Policies or Program
|
|
Health, Intellectual Property
|
Regulatory frameworks related to the Patented Medicines (Notice of Compliance) Regulations as they apply to the protection of intellectual property for innovative medicines.
|
Policies or Program, Regulation
|
Takeda is a patient-focused, values-based, global pharmaceutical company committed to creating innovative therapies through research and development. Established in 1781, Takeda positively affects patients’ lives by translating science into life-changing medicines, focusing on our core therapeutic areas of rare disease, neuroscience, gastroenterology, oncology, vaccines, dermatology and plasma derived therapies.
Alan Walshe, General Manager, Takeda Canada Inc.
Address:
22 Adelaide St W Suite 3800
Toronto, ON M5H 4E3
Canada
Telephone number:
866-397-4473
Takeda Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking